Amgen, the US biopharmaceutical company and its subsidiary, Onyx Pharmaceuticals, have announced that interim analysis of their Phase III clinical trial ASPIRE for relapsed myeloma patients has met the primary endpoint of progression-free survival. The results showed that patients treated with Kyprolis (carfilzomib) in combination with Revlimid and dexamethasone demonstrated significantly longer progression-free survival (median 26.3 months) compared to those treated with Revlimid and dexamethasone (median 17.6 months). The analysis also showed a trend towards improved overall survival among patients who received Kyprolis compared to those who did not. It is hoped that the results from the study will form the basis for regulatory submissions worldwide for Kyprolis as a treatment for myeloma.

Read the full article